Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564496 · ClinicalTrials.gov registry record · NA
Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 73
- Enrollment target
NCT03564496: Completed NA study, sponsored by NYU Langone Health.
NCT03564496 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 73 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564496, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
Study Summary
The objective of this trial is to measure the changes in neural activities during tDCS session using Magnetic Resonance Imaging (MRI). Participants (N=60) (20 Healthy Controls and 40 participants with neurological disorders, ie. multiple sclerosis) will be recruited to complete self-report measures and a brief cognitive assessment and then undergo an hour long stand-alone MRI scan while simultaneously undergoing tDCS stimulation. Methodology for this study is the administration of 15-minutes of of active tDCS during MRI acquisition compared to time without active tDCS.
Primary Outcome
Measured via MRI. CMRO2 is the amount of O2 the brain consumes per unit of time (in μmol O2/100g tissue per minute)
Interventions
- DEVICE tDCS Administration during MRI
- DEVICE Remotely-supervised Daily tDCS Administration
- DEVICE Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2021-09-29 |
| Phase | NA |
What the finished NCT03564496 record still lists
NCT03564496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which tDCS Administration during MRI is the first listed.
NCT03564496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03564496 about?
NCT03564496 is a clinical study titled "Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI". The objective of this trial is to measure the changes in neural activities during tDCS session using Magnetic Resonance Imaging (MRI). Participants (N=60) (20 Healthy Controls and 40 participants with neurological disorders, ie. multiple sclerosis) will be recruited to complete self-report measures ...
What is the current status of trial NCT03564496?
This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2018-07-09. Estimated completion is 2021-09-29.
What interventions are being tested in trial NCT03564496?
The interventions under investigation include: tDCS Administration during MRI (DEVICE), Remotely-supervised Daily tDCS Administration (DEVICE), Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA (DEVICE).
Who is sponsoring clinical trial NCT03564496?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564496's enrollment target sits among peer trials
73 1089th of 2000 higher than 912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI